Skip to main content

Table 1 Correlations between MIC-A-B, ULBP-1, ULBP-2 expression and well-established prognostic factors.

From: NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study

  Total MICAB    ULBP1 ULBP2   
    Low   High   Low   High   Low   High  
  N % N % N % N % N % N % N %
Age               
< 40
40-50
50-60
> = 60
48
145
132
249
8.4
25.3
23.0
43.4
4
28
26
42
4.0
28.0
26.0
42.0
31
86
78
163
8.7
24.0
21.8
45.5
22
62
45
91
10.0
28.2
20.5
41.4
10
32
44
79
6.1
19.4
26.7
47.9
34
85
100
172
8.7
21.7
25.6
44.0
9
42
20
52
7.3
34.1
16.3
42.3
Grade               
I
II
III
80
282
203
14.2
49.9
35.9
22
42
36
22.0
42.0
36.0
38
181
131
10.9
51.7
37.4
39
109
68
18.1
50.5
31.5
9
80
74
5.5
49.1
45.4
41
188
155
10.7
49.0
40.4
27
65
30
22.1
53.3
24.6
Histological type               
Ductal
Lobular
513
53
90.6
9.4
91
9
91.0
9.0
322
29
91.7
8.3
194
22
89.8
10.2
151
12
92.6
7.4
354
30
92.2
7.8
106
16
86.9
13.1
T-status               
T1
T2
T3/4
211
272
72
38.0
49.0
13.0
40
44
12
41.7
45.8
12.5
124
176
47
35.7
50.7
13.5
96
87
31
44.9
40.7
14.5
37
96
26
23.3
60.4
16.4
128
198
54
33.7
52.1
14.2
59
46
12
50.4
39.3
10.3
N-status               
N0
N1-3
307
250
55.1
44.9
60
38
61.2
38.8
181
162
52.8
47.2
118
97
54.9
45.1
69
86
44.5
55.5
196
183
51.7
48.3
74
45
62.2
37.8
ER-status               
Negative
Positive
203
337
37.6
62.4
33
65
33.7
66.3
137
212
39.3
60.7
95
122
43.8
56.2
55
103
34.8
65.2
147
238
38.2
61.8
45
75
37.5
62.5
PgR-status               
Negative
Positive
223
313
41.6
58.4
33
66
33.3
66.7
147
198
42.6
57.4
88
127
40.9
59.1
68
90
43.0
57.0
169
217
43.8
56.2
40
78
33.9
66.1
Her2-status               
No overexpression-
Overexpression
378
44
89.6
10.4
78
6
92.9
7.1
264
36
88.0
12.0
174
20
89.7
10.3
125
15
89.3
10.7
291
29
90.9
9.1
79
14
84.9
15.1
Local Therapy               
MAST-RT
MAST+RT
BCS-RT
BCS+RT
223
108
5
238
38.9
18.8
0.9
41.5
41
17
0
42
41.0
17.0
0.0
42.0
146
66
5
141
40.8
18.4
1.4
39.4
80
46
2
92
36.4
20.9
0.9
41.8
79
33
2
51
47.9
20.0
1.2
30.9
149
83
5
154
38.1
21.2
1.3
39.4
53
15
0
55
43.1
12.2
0.0
44.7
Systemic therapy               
CT alone
HT alone
CT&HT
None
112
75
18
369
19.5
13.1
3.1
64.3
17
8
1
74
17.0
8.0
1.0
74.0
73
54
13
218
20.4
15.1
3.6
60.9
44
31
3
142
20.0
14.1
1.4
64.5
25
29
9
102
15.2
17.6
5.5
61.8
80
54
14
243
20.5
13.8
3.6
62.1
24
16
3
80
19.5
13.0
2.4
65.0
Total 574 100 100 100 358 100 220 100 165 100 391 100 123 100
  1. Missing values are not shown.
  2. AbbreviationsN number of patients; % percentage; ER estrogen receptor; PgR progesterone receptor; HER2 human epidermal growth factor receptor 2; MAST mastectomy; RT radiotherapy; BCS breast conservative surgery; ET endocrine therapy; CT chemotherapy.